Allon animal study confirms blood brain barrier penetration of lead product candidates AL-108 and AL-208

06-Jun-2005

Allon Therapeutics Inc., The Neuro Protection Company(TM), announced that new preclinical animal studies have confirmed that its lead product candidates AL-108 and AL-208 penetrate the blood brain barrier and reach their target therapeutic areas in the central nervous system.

The blood-brain barrier is the system of capillary endothelial cells that protects the brain from harmful substances in the blood stream - and also prevents the permeation of many therapeutic drugs into the brain. Research has established that most neuropeptides, molecules comprised of combinations of amino acids that are released by brain cells as intracellular messengers and growth factors, are normally unable to penetrate the blood-brain barrier when they are given as therapeutics.

However, Allon's preclinical results confirmed the presence of AL-108, an eight amino acid neuropeptide delivered intranasally, and AL-208, an eight amino acid neuropeptide delivered intravenously, in the cerebral spinal fluid of animals after intranasal and intravenous administration of these drug candidates.

Allon's extensive pre-clinical research suggests that its compounds protect against the injury and death of brain cells that occurs after onset of disease or injury to the central nervous system. Pre-clinical models have demonstrated that Allon's compounds have potential in at least eight diseases and injuries of the central nervous system. This research has been published in more than 60 articles in leading peer-reviewed scientific journals.

https://www.bionity.com/en/news/46586/allon-animal-study-confirms-blood-brain-barrier-penetration-of-lead-product-candidates-al-108-and-al-208.html